City
Epaper

New generation of Covid vax shows promising results

By IANS | Updated: August 26, 2022 16:40 IST

Stockholm, Aug 26 A team of researchers is developing a coronavirus vaccine designed to be less sensitive to ...

Open in App

Stockholm, Aug 26 A team of researchers is developing a coronavirus vaccine designed to be less sensitive to mutations and will likely be equipped for future strains.

As per a study, published in the journal EMBO Molecular Medicine, the vaccine showed promising results in mice, and the researchers now hope to be able to take it to safety studies on humans.

"The idea is that it will give broader protection that more resembles that gained after an actual infection and will be a bit more future-proof than the vaccines currently in use," said researcher Matti Sallberg, professor at Karolinska Institutet in Sweden.

In this newly published study, the researchers show that the vaccine protects mice against serious infection from the beta variant of SARS-CoV-2, a variant that can evade the immune response, and activates immune cells (T cells) that recognise the coronavirus found in bats.

Different types of vaccines have been highly instrumental in impeding the pandemic caused by the coronavirus SARS-CoV-2. One challenge is the virus mutability, which is to say, its ability to change to avoid the human defence response.

Most current vaccines are based on using parts of the coronavirus's so-called spike protein to trigger the body's immune response to the virus. It is a good vaccine protein to use, but unfortunately, it is the spike protein where frequent mutations occur, which can impact the vaccines' effectiveness.

The researchers are, therefore, developing a vaccine containing more parts of the virus, including ones that do not mutate at the same rate as the spike protein.

The vaccine is a DNA vaccine, which means that it comprises DNA sequences that, when injected into the body, make the cells produce the proteins that the DNA sequences contain instructions for, the researchers said.

In this case, it concerns DNA for parts of the spike protein from three different coronavirus variants and DNA for another two virus proteins, called M and N, where mutations are less common.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Matti sallbergswedenStockholmKarolinska InstitutetEmbo molecular medicine
Open in App

Related Stories

InternationalElisabet Lann: Sweden Health Minister Collapses During Live Press Conference; Video Surfaces

InternationalSweden Mass Shooting: 3 Killed, Multiple Injured in Uppsala Attack

InternationalSweden Shooting: Five People Shot at School in Orebro

TechnologyMpox Outbreak 2024: Thailand Detects First Suspected Case of New Clade 1b Strain After Sweden

InternationalRussia-Ukraine War: Vladimir Putin Vows to Deploy Troops Along Finland Border After It Joins NATO

Health Realted Stories

HealthIndia rapidly progressing in AI, digital infra sectors to become a developed nation: Experts

HealthUN report urges nations to tackle inequalities driving pandemics for global health security

HealthIs Tomato Ketchup Safe for Kids? Shocking Side Effects of Market Ketchup Revealed

HealthDengue fever cases surge in Vietnam's capital Hanoi

HealthHeart Attack Alert: Why Shortness of Breath Could Signal Hidden Health Trouble